US FDA Changes Data Source For GDUFA II Facility Fee Setting
Executive Summary
Agency primarily uses application data instead of facility self-identification lists to determine FY 2018 generic drug user fees.
You may also be interested in...
Generic User Fee Transition A Little Bumpy For Contract Manufacturers
Problems with self-identification process caused by timing of legislative renewal may have affected figures used by US FDA to calculate FY 2018 GDUFA fees.
Generic User Fee Transition A Little Bumpy For Contract Manufacturers
Problems with self-identification process caused by timing of legislative renewal may have affected figures used by US FDA to calculate FY 2018 GDUFA fees.
Generic Drug User Fees Will Jump More Than 50% In FY 2018
GDUFA II's fee structure shifts burden from manufacturers to sponsors though 'ANDA holder fee.'